NCT06194799
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Enrolling by Invitation
PHASE3Ages 55–95InterventionalTreatmentACADIA Pharmaceuticals Inc.
~752 participants
Updated 2026-07-02 on ClinicalTrials.gov
What's tested:ACP-204
At a glance
Recruiting sites
0 of 76 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Treatment-emergent adverse events
Measured over 52 Weeks
Conditions
Where it's being run
76 sites across 20 statesFlorida13
Serbia9
Brazil7
Bulgaria7
Czechia5
Texas4
Chile4
South Korea4
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Subject has successfully completed ACP-204-006 study
Male or female (age 55 to 95 years old): female must be of non-childbearing potential, male must take appropriate contraceptive method if partner has childbearing potential
Subject has a designated study partner/caregiver
Subjects are able to complete all study visits with a study partner/caregiver
Signed inform consent form with a caregiver or legal representative
Exclusion
Requires treatment with a medication prohibited by the protocol
Is in hospice and receiving end-of-life palliative care, or has become bedridden
Unstable clinically significant medical condition other than AD
Any medical condition that in the opinion of the investigator may affect safety or ability to complete the study
What this trial measures
- Treatment-emergent adverse events52 Weeks
Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs) over 52 weeks of treatment. The Safety population consists of all subjects who received at least one dose of study drug in this study.